Piper Sandler raised the firm’s price target on NeoGenomics (NEO) to $12 from $11 following quarterly results. The firm keeps an Overweight rating on the shares.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NEO:
- NeoGenomics to present RaDaR ST bridging study at ISLB 2025
- NeoGenomics price target raised to $11 from $6.50 at BofA
- NeoGenomics Reports Strong Revenue Growth Amid Rising Losses
- NeoGenomics Inc. Earnings Call: Clinical Growth Amid Pharma Challenges
- Strong Growth Prospects for NeoGenomics: Buy Rating with Increased Price Target